Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
As recently analysed by Matthew Herper, the launch of Biogen Idec ‘s oral multiple sclerosis treatment Tecfidera in the US has surpassed what were already lofty expectations. As a result of rapid uptake among neurologists, analysts have revisited their forecasts for the product and Biogen Idec’s share price has accelerated towards an increase of 60 percent since December. European approval of Tecfidera was expected to follow this week and anticipated to be a key catalyst of further growth. However, Biogen Idec announced on May 30 that it had voluntarily asked for approval to be delayed – a move that is expected to subsequently push launch of Tecfidera some way into the second half of 2013.
Help employers find you! Check out all the jobs and post your resume.
